| MA |
DI | WO |
DO |
VR | ZA | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| VM | NM | VM | NM | VM | NM | VM | NM | VM | NM | VM | NM |
- Maandag: namiddag
- Woensdag: voormiddag
- Vrijdag: namiddag
Dr. Bossuyt is niet geconventioneerd
Raadpleging Imeldaziekenhuis
Contact: 015 50 51 11
Raadpleging Somedi
maandag voormiddag
Contact: 015 25 89 11
Wie ben ik?
- maagdarmspecialist in IBD kliniek van Imelda
- co-director van Imelda GI clinical research center
- pionier in werken met e-health en artificial intelligence binnen inflammatoire darmziekten
- lid editorial board van de Journal of Crohn’s and Colitis
- past-chair van het wetenschappelijk comité, huidig secretaris en president-elect van het Belgisch IBD onderzoeksgroep (BIRD)
- lid Clinical Research Committee van de Europese IBD vereniging
- >100 onderzoeksartikels in internationale tijdschriften (Lancet, Gut, Gastroenterology, Lancet Gastro & Hep, JCC, Clinical Gastro & Hep (h-index 30))
- spreker op talrijke internationale congressen
Loopbaan
- 2004: afstudering magna cum laude van opleiding geneeskunde aan KU Leuven
- vervolging opleiding tot maagdarmspecialist in Kortrijk, Roeselare, Bonheiden en Leuven
- bijkomende opleiding gespecialiseerde endoscopie aan het Amsterdam Medisch Centrum
- 2010-2015: consultent-staflid voor echo-endoscopie in Gasthuisberg, Leuven
- 2021: doctoraatsthesis ‘Value of endoscopic scoring and imaging for the prognosis and follow up of IBD’ aan KU Leuven
ENGLISH
Dr. Peter Bossuyt is a gastroenterologist at the IBD clinic in the Imelda General Hospital in Bonheiden, Belgium. He is also Co-director of the Imelda GI Clinical Research Centre in Bonheiden. Dr. Bossuyt studied medicine at the Catholic University of Leuven, Belgium, and graduated in 2004 with magna cum laude. He pursued his GI fellowship in Kortrijk, Roeselare, Bonheiden and Leuven. After completing his GI fellowship, he took up a fellowship in advanced endoscopy at the Academic Medical Centre, Amsterdam. Between 2010 and 2015 he was a consulting staff member for endoscopic ultrasound at the University Hospitals of Leuven. In 2021 he obtained his PhD degree entitled, Value of endoscopic scoring and imaging for the prognosis and follow up of IBD, at the Catholic University of Leuven. His research focuses on clinical trials in IBD and the definitions of endoscopic and imaging targets in IBD. He is a pioneer in working with e-health tools and AI in IBD. He is an editorial board member of the Journal of Crohn’s and Colitis, past-chair of the Scientific Committee and past secretary and president of the Belgian IBD Research and Development Group, and past board member of ECCO’s Clinical Research Committee, ClinCom. He has (co-)authored >120 papers in international peer-reviewed journals (Lancet, Gut, Gastroenterology, Lancet Gastro & Hep, JCC, Clinical Gastro & Hep among others; h-index 35) and was invited speaker at multiple international congresses.
Belangrijkste publicaties:
Automatic, computer-aided determination of endoscopic and histological inflammation in patients with mild to moderate ulcerative colitis based on red density. Bossuyt P, Nakase H, Vermeire S, de Hertogh G, Eelbode T, Ferrante M, Hasegawa T, Willekens H, Ikemoto Y, Makino T, Bisschops R. Gut. 2020 Oct;69(10):1778-1786.
Computer-Aided Diagnosis With Monochromatic Light Endoscopy for Scoring Histologic Remission in Ulcerative Colitis. Bossuyt P, De Hertogh G, Eelbode T, Vermeire S, Bisschops R. Gastroenterology. 2021 Jan;160(1):23-25.
Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Colombel JF, Panaccione R, Bossuyt P, Lukas M, Baert F, Vaňásek T, Danalioglu A, Novacek G, Armuzzi A, Hébuterne X, Travis S, Danese S, Reinisch W, Sandborn WJ, Rutgeerts P, Hommes D, Schreiber S, Neimark E, Huang B, Zhou Q, Mendez P, Petersson J, Wallace K, Robinson AM, Thakkar RB, D'Haens G. Lancet. 2018 Dec 23;390(10114):2779-2789. doi: 10.1016/S0140-6736(17)32641-7. Epub 2017 Oct 31.
Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. D'Haens G, Panaccione R, Baert F, Bossuyt P, Colombel JF, Danese S, Dubinsky M, Feagan BG, Hisamatsu T, Lim A, Lindsay JO, Loftus EV Jr, Panés J, Peyrin-Biroulet L, Ran Z, Rubin DT, Sandborn WJ, Schreiber S, Neimark E, Song A, Kligys K, Pang Y, Pivorunas V, Berg S, Duan WR, Huang B, Kalabic J, Liao X, Robinson A, Wallace K, Ferrante M. Lancet. 2022 May 28;399(10340):2015-2030.
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial. Ferrante M, Panaccione R, Baert F, Bossuyt P, Colombel JF, Danese S, Dubinsky M, Feagan BG, Hisamatsu T, Lim A, Lindsay JO, Loftus EV Jr, Panés J, Peyrin-Biroulet L, Ran Z, Rubin DT, Sandborn WJ, Schreiber S, Neimark E, Song A, Kligys K, Pang Y, Pivorunas V, Berg S, Duan WR, Huang B, Kalabic J, Liao X, Robinson A, Wallace K, D'Haens G. Lancet. 2022 May 28;399(10340):2031-2046.
Infliximab Exposure Associates With Radiologic Evidence of Healing in Patients With Crohn's Disease. Bossuyt P, Dreesen E, Rimola J, Devuysere S, De Bruecker Y, Vanslembrouck R, Laurent V, Zappa M, Savoye-Collet C, Pariente B, Filippi J, Baert F, D'haens G, Laharie D, Peyrin-Biroulet L, Vermeire S; Tailorix study group. Clin Gastroenterol Hepatol. 2020 Apr 28:S1542-3565(20)30597-8. doi: 10.1016/j.cgh.2020.04.052. Online ahead of print.
Patient-reported Outcomes and Disability Are Associated with Histological Disease Activity in Patients with Ulcerative Colitis: Results from the APOLLO Study. Verstockt B, Pouillon L, Ballaux F, Jorissen C, Hoefkens E, Lembrechts N, Bossuyt P. J Crohns Colitis. 2023 Jul 5;17(7):1046-1054.
Externe links